Human Tissue Samples
Human brain tissue was acquired from Rush University (USA), the New York University Alzheimer’s Disease Center (USA), and the Sydney Brain Bank (Australia), which all provide human brain tissue from ethically approved longitudinally assessed regional brain donor programs on neurodegenerative diseases. Brain tissue was acquired under protocols with Institutional Review Board (IRB) approval at NYU Grossman School of Medicine, Rush University and the Southeastern Sydney and Illawarra Local Health District and the Universities of New South Wales and Sydney, Australia. In all cases, written informed consent for research was obtained from the patient or legal guardian, and the material used had appropriate ethical approval for use in this project. All patients’ data and samples were coded and handled according to NIH and NHMRC guidelines to protect patients’ identities.
Inferior temporal cortex tissue was obtained from Rush University, which was from cases part of the Religious Orders Study (ROS) and Memory and Aging Project (MAP) cohorts [13]. Clinical assessment and neuropathology were performed at Rush University [16, 79, 106]. Cases were stratified into control, preclinical AD, MCI, and advanced AD experimental groups using a combination of both clinical and neuropathological criteria. Cases were initially stratified by the clinical cognitive final consensus diagnosis that was generated by a neurologist with expertise in dementia by a review of all available cognitive data that was blinded to post-mortem data. The following neuropathological inclusion criteria was then used to refine case selection in each group: neuropathological ABC score of A0-1/B0-2/C0-1 for control, A2-3/B1-2/C2-3 for MCI, and A3/B3/C3 for AD. Control cases were further stratified into low-pathology controls and preclinical AD cases by staining for Aβ and confirmation of a moderate Aβ plaque load in the temporal cortex. Cases were prioritized to exclude those with high TDP-43 and Lewy body pathology. Tissue included in this study from this cohort included 8 µm formalin-fixed paraffin-embedded (FFPE) sections of the inferior temporal cortex from control (n = 12), preclinical AD (n = 10), MCI (n = 12), and AD cases (n = 12).
Hippocampal tissue used in this study was obtained from New York University Alzheimer’s Disease Center (USA). This tissue included 8 µm FFPE sections containing the hippocampus from n = 7 AD and n = 4 cognitively unimpaired age-matched controls. Superior frontal cortex tissue was obtained from the Sydney Brain Bank (Australia). This included 8 µm FFPE sections from n = 10 AD and n = 7 cognitively unimpaired age-matched control cases and fresh frozen tissue from n = 7 AD, n = 5 MCI, and n = 6 cognitively unimpaired age-matched controls. Case-specific details are summarized in Table 1.
Table 1
Case ID | Brain Region | Age | Sex | PMI | ABC Score | Western Blot Characterisation | SMOC1 IP | SMOC1 / Aβ (4G8) IHC | SMOC1 / pAβ IHC | SMOC1 / pTau (AT8) IHC | Cell Type IHC |
Control 1 | SFC | 93 | F | 21 | A1 B0 C0 | x | | x | | | |
Control 2 | SFC | 79 | M | 8 | A0 B1 C0 | x | x | x | | | |
Control 3 | SFC | 89 | F | 23 | A1 B1 C0 | x | x | x | | | |
Control 4 | SFC | 84 | M | 36 | A1 B0 C0 | x | | | | | |
Control 5 | SFC | 89 | M | 27 | A0 B2 C0 | x | | | | | |
Control 6 | SFC | 97 | F | 25 | A1 B2 C0 | x | x | | | | |
MCI 1 | SFC | 84 | F | 6 | A3 B2 C2 | x | | | | | |
MCI 2 | SFC | 88 | F | 26 | A3 B2 C2 | x | x | | | | |
MCI 3 | SFC | 89 | M | 33 | A3 B2 C1 | x | x | | | | |
MCI 4 | SFC | 84 | F | 34 | A3 B2 C2 | x | x | | | | |
MCI 5 | SFC | 95 | F | 17 | A3 B2 C2 | x | | | | | |
AD 1 | SFC | 80 | F | 32 | A3 B3 C3 | x | | | | | |
AD 2 | SFC | 86 | M | 9 | A3 B3 C3 | x | x | | | | |
AD 3 | SFC | 85 | F | 10 | A3 B3 C3 | x | x | | | | |
AD 4 | SFC | 75 | F | 14 | A3 B3 C3 | x | | x | | | |
AD 5 | SFC | 92 | M | 21 | A3 B3 C3 | x | x | | | | |
AD 6 | SFC | 70 | M | 23 | A3 B3 C3 | x | | x | | | |
AD 7 | SFC | 73 | M | 26 | A3 B3 C3 | x | | x | | | |
Control 7 | SFC | 68 | M | 11 | A0 B0 C0 | | | x | | | |
Control 8 | SFC | 90 | F | 58 | A1 B0 C0 | | | x | | | |
Control 9 | SFC | 84 | M | 9 | A1 B1 C1 | | | x | | | |
Control 10 | SFC | 93 | F | 15 | A2 B1 C1 | | | x | | | |
AD 8 | SFC | 66 | M | 9 | A3 B3 C3 | | | x | | | |
AD 9 | SFC | 91 | F | 6 | A3 B3 C2 | | | x | | | |
AD 10 | SFC | 64 | F | 18 | A3 B3 C3 | | | x | | | |
AD 11 | SFC | 70 | M | 8 | A3 B3 C2 | | | x | | | |
AD 12 | SFC | 74 | M | 35 | A3 B3 C3 | | | x | | | |
AD 13 | SFC | 69 | M | 19 | A3 B3 C3 | | | x | | | |
Control 11 | ITC | 82 | M | 7 | A1 B1 C0 | | | x | | | |
Control 12 | ITC | 90 | F | 26 | A0 B1 C0 | | | x | | | |
Control 13 | ITC | 87 | M | 4 | A0 B1 C0 | | | x | | | |
Control 14 | ITC | 95 | F | 5 | A1 B1 C0 | | | x | | | |
Control 15 | ITC | 76 | F | 6 | A1 B0 C0 | | | x | | | |
Control 16 | ITC | 91 | F | 15 | A0 B2 C0 | | | x | | | |
Control 17 | ITC | 80 | M | 17 | A0 B1 C0 | | | x | | | |
Control 18 | ITC | 81 | F | 5 | A1 B1 C1 | | | x | | | |
Control 19 | ITC | 93 | F | 3 | A0 B2 C0 | | | x | | | |
Control 20 | ITC | 83 | F | 1 | A1 B1 C0 | | | x | | | |
Control 21 | ITC | 91 | M | 7 | A1 B2 C0 | | | x | | | |
Control 22 | ITC | 84 | M | 11 | A1 B1 C0 | | | x | | | |
Preclinical 1 | ITC | 89 | F | 27 | A2 B2 C2 | | | x | | | |
Preclinical 2 | ITC | 80 | M | 27 | A2 B2 C2 | | | x | | | |
Preclinical 3 | ITC | 85 | F | 5 | A2 B2 C2 | | | x | | | x |
Preclinical 4 | ITC | 83 | M | 6 | A2 B1 C1 | | | x | | | |
Preclinical 5 | ITC | 85 | F | 6 | A2 B2 C2 | | | x | | | |
Preclinical 6 | ITC | 78 | M | 10 | A1 B1 C1 | | | x | | | |
Preclinical 7 | ITC | 85 | F | 6 | A1 B2 C1 | | | x | | | |
Preclinical 8 | ITC | 94 | F | 12 | A2 B1 C1 | | | x | | | |
Preclinical 9 | ITC | 86 | M | 18 | A1 B2 C2 | | | x | | | |
Preclinical 10 | ITC | 70 | M | 21 | A2 B0 C2 | | | x | | | |
MCI 6 | ITC | 84 | F | 6 | A2 B2 C1 | | | x | | | |
MCI 7 | ITC | 94 | F | 12 | A2 B1 C2 | | | x | | | |
MCI 8 | ITC | 95 | F | ND | A2 B2 C2 | | | x | | | |
MCI 9 | ITC | 84 | M | 5 | A3 B2 C2 | | | x | | | |
MCI 10 | ITC | 85 | M | 21 | A2 B2 C2 | | | x | | | |
MCI 11 | ITC | 89 | M | 5 | A2 B2 C2 | | | x | | | |
MCI 12 | ITC | 75 | M | 16 | A2 B2 C2 | | | x | | | |
MCI 13 | ITC | 91 | F | 13 | A2 B2 C3 | | | x | | | |
MCI 14 | ITC | 85 | F | 18 | A2 B2 C2 | | | x | | | |
MCI 15 | ITC | 88 | F | 6 | A2 B3 C3 | | | x | | | |
MCI 16 | ITC | 98 | F | 7 | A2 B2 C2 | | | x | | | |
MCI 17 | ITC | 89 | F | 20 | A1 B2 C2 | | | x | | | |
AD 14 | ITC | 83 | F | 2 | A3 B3 C3 | | | x | | | |
AD 15 | ITC | 81 | F | 6 | A3 B3 C3 | | | x | | | |
AD 16 | ITC | 84 | F | 17 | A3 B3 C3 | | | x | | | x |
AD 17 | ITC | 90 | F | 8 | A3 B3 C3 | | | x | | | |
AD 18 | ITC | 88 | F | 26 | A3 B3 C3 | | | x | | | |
AD 19 | ITC | 93 | M | 6 | A3 B3 C3 | | | x | | | |
AD 20 | ITC | 87 | M | 9 | A3 B3 C3 | | | x | | | |
AD 21 | ITC | 95 | F | 8 | A3 B3 C3 | | | x | | | x |
AD 22 | ITC | 96 | F | 14 | A3 B3 C3 | | | x | | | |
AD 23 | ITC | 87 | M | 4 | A3 B3 C3 | | | x | | | x |
AD 24 | ITC | 96 | M | 5 | A3 B3 C3 | | | x | | | x |
AD 25 | ITC | 72 | F | 3 | A3 B3 C3 | | | x | | | |
Control 23 | H | 77 | M | ND | A0 B0 C0 | | | x | | x | |
Control 24 | H | 59 | M | ND | A1 B0 C0 | | | x | | x | |
Control 25 | H | 71 | F | ND | ND | | | x | | x | |
Control 26 | H | 81 | F | ND | ND | | | x | | x | |
AD 26 | H | 89 | F | ND | A3 B3 C3 | | | x | x | x | |
AD 27 | H | 79 | F | ND | A3 B3 C3 | | | x | x | x | |
AD 28 | H | 73 | M | ND | A3 B3 C3 | | | x | x | x | |
AD 29 | H | 72 | F | ND | A3 B3 C3 | | | x | x | x | |
AD 30 | H | 85 | F | ND | A3 B3 C3 | | | x | | x | |
AD 31 | H | 92 | F | ND | A3 B3 C3 | | | x | x | x | |
AD 32 | H | 84 | F | ND | A3 B3 C3 | | | x | | x | |
IP; immunoprecipitation, IHC; immunohistochemistry, PMI; postmortem interval, SFC; superior frontal cortex, ITC; inferior temporal cortex, H; hippocampus, ND; not determined.
Immunohistochemistry for Image Analysis
FFPE tissue sections underwent fluorescent immunohistochemistry using the method described in [37]. Briefly, sections were deparaffinized and rehydrated through a series of xylene and ethanol washes. Antigen retrieval was achieved using 99% formic acid for 7 min followed by boiling in citrate buffer for 21 min (0.05 mM sodium citrate, 0.05% Tween-20, pH 6). Sections were blocked in 10% normal goat serum and incubated with anti-SMOC1 (abcam, ab200219, 1:100) combined with either anti-Aβ (BioLegend, 4G8, 800701, 1:1000), anti-pyroglutamated Aβ (BioLegend, 822301, 1:250) or anti-pTau (ThermoFisher, AT8, MN1020, 1:500) in 4% normal goat serum overnight at 4oC. AlexaFluor488-, AlexaFluor647-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, 1:500) and Hoechst 33342 (Sigma, B2261, 1:1000) were applied for 2 h at room temperature prior to coverslipping with Antifade ProLong Glass (Invitrogen, P36984). Whole slide images were acquired using an Olympus VS200 Slide Scanner at 10x (SMOC1/4G8) or 20x (SMOC1/AT8) magnification. For SMOC1/pyroglutamated Aβ, whole slides were captured across multiple images on a Leica Thunder Fluorescence Microscope at 10x magnification with 10% stitching. Representative 60x images were captured on a Nikon C2 Confocal microscope. Empty channel 568 was captured to allow for autofluorescence subtraction.
Immunohistochemistry for Cell Type Investigation
FFPE tissue sections underwent deparaffinization and rehydration as above, prior to boiling in citrate buffer for 21 min (10 mM sodium citrate, 0.05% Tween-20, pH 6). Sections were blocked in 10% normal horse serum and incubated with anti-SMOC1 (abcam, ab200219, 1:100) and anti-Aβ (BioLegend, 4G8, 800701, 1:1000), combined with either anti-PDGFRa (R&D Systems, AF-307, 1:250), anti-Olig2 (R&D Systems, AF2418, 1:500), anti-GFAP (Novus Biologicals, NOVNBP1-05198, 1:1500), anti-Iba1 (abcam, ab5076, 1:500) or anti-NeuN (Merck, ABN91, 1:500) in 4% normal horse serum overnight at 4°C. CF488- (Sigma, SAB4600036, 1:1000), AlexaFluor594- (Jackson, 703-585-155, 1:1500), AlexaFluor647- (Thermo, A32849, 1:1000), AlexaFluor750- (abcam, ab175739, 1:500) conjugated secondary antibodies and Hoechst 33342 (Sigma, B2261, 1:1000) were applied for 2 h at room temperature prior to coverslipping with Antifade ProLong Glass (Invitrogen, P36984). Whole slide images were acquired using an Olympus VS200 Slide Scanner at 40x magnification. Representative 60x images were captured on a Nikon C2 Confocal microscope.
SMOC1/4G8 Immunohistochemistry Analysis
SMOC1 load in amyloid plaques was assessed in temporal cortex, frontal cortex and hippocampal sections. Gray matter regions of each frontal cortex and temporal cortex section were manually annotated in QuPath (v0.4.4). For hippocampal sections, the hippocampus was defined as the combined area containing CA1-4 and subiculum. A pixel classifier was trained in QuPath to recognize amyloid plaques and was used to generate a mask of all plaques in grey matter or hippocampus for each section. Images were exported as .tif images with corresponding plaque masks. Plaque masks were applied to images in ImageJ2 (v2.14.0), and empty channel 568 subtracted from 488 to minimize autofluorescent signal. For each cohort, a SMOC1 threshold was determined based on the negative control, and thresholded SMOC1 signal measured within masked regions.
SMOC1/AT8 Immunohistochemistry Analysis
SMOC1 load in AT8-immunoreactive pTau lesions was assessed in hippocampal sections. Region annotation, image export and background subtraction was performed in QuPath as above for the hippocampus (CA1-4 and subiculum). AT8-positive signal was masked in ImageJ2, and SMOC1 signal within masked regions was thresholded and measured.
SMOC1/pyroglutamated Aβ Immunohistochemistry Analysis
SMOC1 load in pyroglutamated Aβ (pAβ) lesions was assessed in hippocampal sections. Hippocampus regions (CA1-4 and subiculum) were manually annotated in ImageJ2. pAβ-positive signal was masked in ImageJ2, and SMOC1 signal within masked regions thresholded and measured.
Tissue Homogenization
Tissue homogenization was performed as per [38]. Briefly, fresh frozen frontal cortex tissue was pulverized and dounce homogenized in 20% w/v ice-cold homogenization buffer (50 mM HEPES pH 7.0, 250 mM sucrose, 1 mM EDTA, protease and phosphatase inhibitor cocktails). Total brain homogenates were aliquoted and stored at -80°C.
Co-Immunoprecipitation
2 µg of SMOC1 antibody (abcam, ab200219) or rabbit IgG control antibody (Invitrogen, 02-6102) was added to 300 µg of total brain homogenate and brought up to 350 µL with homogenization buffer. Samples were incubated for 24 h at 4°C with rotation (25 rpm) to allow antibody binding. Samples were then incubated with Dynabeads (1.5 mg/sample) and incubated on a rotator for 24 h at 4°C. Elution was conducted by adding 20 µL of 1x LDS Sample Buffer to beads and incubating for 15 min (70°C, 1000 rpm). The co-IP product was transferred to a clean tube and stored at -20°C until use.
Western Blot Analysis
Relative protein content of co-IP products and brain homogenates were visualized by Western Blot. Co-IP products were blotted using equal volumes per well. Brain homogenate total protein concentration was determined using Pierce BCA and normalized with deionized water. Samples were denatured by boiling at 95°C for 5 min with DTT and LDS Sample Buffer. Proteins were resolved on 4–12% or 12% NuPage Bis-Tris gels and transferred to PVDF membranes. Membranes were blocked in 5% skim milk (Aβ, Rb pTau, PHF-1) or 5% skim milk with 5% NGS (SMOC1) in TBST and then incubated with anti-Aβ (CST 8243, 1:1000 dilution), anti-SMOC1 (abcam 200219, 1:1000) or anti-PHF-1 (Peter Davies [48], 1:1000) overnight at 4°C. Secondary HRP-linked IgG (Cytiva NA931V, NA934V, 1:25,000) was applied for 2 h and ECL signal recorded on an iBright CL1500 (Invitrogen).
Recombinant Aβ42 and SMOC1 Protein Preparation
Aβ42 was prepared as per [110]. Briefly, recombinant lyophilized Aβ42 (rPeptide, A-1163-1) was resuspended in cold 50 mM NaOH to a concentration of 1 mg/ml, sonicated for 5 minutes in an ice bath, and passed through a 0.22 µm filter (10,000 x g, 1min) to remove larger aggregates. Filtrate concentration was determined via Nanodrop (A280, ε = 1490cm− 1M− 1) prior to storage at -20°C for no longer than one month. To remove any large aggregates formed during thawing, thawed Aβ42 aliquots underwent an additional round of sonication and filtration, and concentration was re-measured as above.
Lyophilized recombinant His-tagged SMOC1 (abcam, ab276453) was resuspended in ice-cold PBS and centrifuged at 16,000 x g for 10 minutes at 4°C to remove large aggregates. The supernatant was collected and dialyzed overnight against fresh PBS to eliminate contaminants. Protein concentration was determined via Nanodrop (A280, ε = 39765cm− 1M− 1) prior to storage at -20°C.
Aβ42 Thioflavin-T Assays
Thioflavin-T (ThT) assays were set up by initially adding neutralization buffer (100 mM phosphate buffer, pH 6.5) to each well of a 96-well half-area non-binding microplate (Corning 3881). SMOC1 or BSA at 0.125–1.25 µM was added prior to addition of Aβ42 at a final concentration of 2.5 µM. Control samples with SMOC1 or BSA alone at 1.25 µM were included to assess baseline ThT fluorescence. Plates were immediately transferred to a POLARstar Omega microplate reader (BMG Labtech) at 37°C. ThT fluorescence was measured at Ex/Em 440/480 nm for 50 h under quiescent conditions. Lag times were calculated as per [26, 91]. Post-assay, samples were processed for SDS-PAGE and TEM analysis.
Preparation of Mature Aβ42 Fibrils
Aβ42 in 50 mM NaOH was neutralized (100 mM phosphate buffer, pH 6.5) to a final concentration of 20 uM and incubated for 32 h at 37°C. Following incubation, fibrils were diluted to a final concentration of 10 µM in the presence or absence of SMOC1 or BSA at a molar ratio of 10:1. SMOC1 and BSA alone at 1 µM were included as additional controls. All samples were incubated for 2 h at RT prior to SDS-PAGE and TEM analysis.
SDS-PAGE
A portion of each ThT assay sample was reserved (‘Total’) with the remaining solution centrifuged at 4°C (80,000 x g, 20 min). The supernatant was collected (‘Soluble fraction’) and the pellet resuspended in 8 M urea (‘Pellet fraction’). Samples were denatured by boiling at 95°C for 5 min with DTT and Novex Tricine SDS Sample Buffer (ThermoFisher, LC1676). Proteins were resolved on NuPAGE 10–20% Tricine Protein Gels, stained with Sypro-Ruby protein gel stain and imaged using an iBright CL1500 (Invitrogen).
Transmission Electron Microscopy (TEM)
5 µL of each sample was applied to a glow-discharged, standard Formvar on carbon film copper TEM grids (ProScitech, GSFC100CU) for 2 min. Excess liquid was removed with filter paper, and grids washed three times with water. Each grid was incubated with 10 µl of 10 nm Ni-NTA-Nanogold (Nanoprobes, 2084-3ML, 1:50) followed by 3x buffer washes (20 mM Tris, pH 7.6, 150 mM NaCl, 8 mM imidazole) as per the manufacturer’s instructions. Grids were stained with 2% uranyl acetate solution for 2 min and air-dried overnight. Replicate samples were imaged by TEM and showed consistent morphology. For analysis of fibril length, n ≥ 20 TEM images per sample were collected using an FEI Tecnai T12 at 120 kV and fibril lengths calculated using ImageJ.
Statistical Analysis
All results were analyzed in GraphPad Prism (v10.0.3). Each dataset was assessed for Gaussian distribution using a Shapiro-Wilk normality test. For immunohistochemistry analysis, normally distributed datasets were analyzed using Brown-Forsyth and Welch ANOVA tests with Dunnett’s T3 post-hoc, or Pearson correlation where appropriate. Non-normal datasets were analyzed using Kruskal-Wallis test with Dunn’s post-hoc, nonparametric Spearman correlation or Mann-Whitney two-tailed U test where applicable. Statistics were not performed on pAβ/4G8 staining comparisons due to differences in image analysis methods. Thioflavin T assay results were fitted with Boltzmann sigmoidal curves and analyzed using an ordinary two-way ANOVA with Tukey’s post-hoc. Aβ42 fibril lengths were analyzed by a Kruskal-Wallis test with Dunn’s post-hoc.